| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Hans-Peter Vornlocher | Q50638445 |
| P2093 | author name string | Judy Lieberman | |
| John Maraganore | |||
| Antonin de Fougerolles | |||
| P2860 | cites work | RNA interference targeting Fas protects mice from fulminant hepatitis | Q78961966 |
| Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes | Q79450299 | ||
| RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics | Q81255508 | ||
| Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA | Q81547115 | ||
| Different delivery methods-different expression profiles | Q81554477 | ||
| Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors | Q81772313 | ||
| Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis | Q83856360 | ||
| Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma | Q83963455 | ||
| Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7 | Q24295641 | ||
| A computational study of off-target effects of RNA interference | Q24521012 | ||
| Induction of the interferon response by siRNA is cell type- and duplex length-dependent | Q24544339 | ||
| Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle | Q24560011 | ||
| MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies | Q24681266 | ||
| A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids | Q24794521 | ||
| Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake | Q24794543 | ||
| An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons | Q24810749 | ||
| siRNA-mediated off-target gene silencing triggered by a 7 nt complementation | Q24812419 | ||
| A single siRNA suppresses fatal encephalitis induced by two different flaviviruses | Q25255046 | ||
| Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging | Q25255924 | ||
| Asymmetry in the assembly of the RNAi enzyme complex | Q27860763 | ||
| Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans | Q27860867 | ||
| MicroRNAs: small RNAs with a big role in gene regulation | Q27860896 | ||
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| Functional siRNAs and miRNAs Exhibit Strand Bias | Q27861038 | ||
| Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes | Q28115751 | ||
| A microRNA in a multiple-turnover RNAi enzyme complex | Q28131835 | ||
| Therapeutic potential of RNA interference against cancer | Q28253746 | ||
| Mechanisms of gene silencing by double-stranded RNA | Q28282560 | ||
| Strategies for silencing human disease using RNA interference | Q28288535 | ||
| Rational siRNA design for RNA interference | Q29614450 | ||
| Expression profiling reveals off-target gene regulation by RNAi | Q29615965 | ||
| A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine | Q29616154 | ||
| Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. | Q30708934 | ||
| Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. | Q30944070 | ||
| RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. | Q31120024 | ||
| Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization | Q33201362 | ||
| Aptamers: an emerging class of therapeutics | Q33211036 | ||
| Designing siRNA that distinguish between genes that differ by a single nucleotide | Q33257088 | ||
| Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung | Q33936962 | ||
| In vivo activity of nuclease-resistant siRNAs | Q34365687 | ||
| RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo | Q34379366 | ||
| Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication | Q34417017 | ||
| Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs | Q34436572 | ||
| 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets | Q34496075 | ||
| Inhibition of influenza virus production in virus-infected mice by RNA interference | Q34514513 | ||
| Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo | Q34522857 | ||
| Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference | Q34526756 | ||
| Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways | Q34530552 | ||
| Off-target effects by siRNA can induce toxic phenotype | Q34703017 | ||
| Prospects for cationic polymers in gene and oligonucleotide therapy against cancer | Q34804863 | ||
| Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells | Q35031898 | ||
| Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis | Q35094492 | ||
| Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. | Q35676793 | ||
| Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. | Q35691719 | ||
| GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery | Q35739328 | ||
| Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. | Q36103830 | ||
| Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents | Q36321052 | ||
| Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs | Q36368352 | ||
| Recent approaches to intracellular delivery of drugs and DNA and organelle targeting | Q36533366 | ||
| siRNA and isRNA: two edges of one sword | Q36550881 | ||
| On the art of identifying effective and specific siRNAs | Q36575382 | ||
| RNAi therapeutics: a potential new class of pharmaceutical drugs | Q36654918 | ||
| Lipid-based nanoparticles for nucleic acid delivery | Q36718049 | ||
| Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death | Q37401041 | ||
| Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference | Q37704644 | ||
| Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras | Q38311731 | ||
| Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque | Q39362979 | ||
| siRNA relieves chronic neuropathic pain | Q39383106 | ||
| Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer | Q40226437 | ||
| Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. | Q40255084 | ||
| Aptamer mediated siRNA delivery | Q40272685 | ||
| A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes | Q40297980 | ||
| An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection | Q40347915 | ||
| Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma | Q40365729 | ||
| Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). | Q40428170 | ||
| Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. | Q40541858 | ||
| A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics | Q40554467 | ||
| Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity | Q41626666 | ||
| Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing | Q41627339 | ||
| RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. | Q42799200 | ||
| Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides | Q42809859 | ||
| City initiative: baby steps to a better future. | Q43172006 | ||
| Engineering mucosal RNA interference in vivo | Q44055198 | ||
| Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. | Q45095142 | ||
| Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs | Q45147309 | ||
| Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. | Q45151534 | ||
| Pegaptanib for neovascular age-related macular degeneration | Q45206481 | ||
| Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. | Q45887309 | ||
| Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. | Q46188888 | ||
| Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence | Q46462650 | ||
| siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain | Q46531749 | ||
| Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo | Q46847636 | ||
| Suppression of discoidin domain receptor 1 by RNA interference attenuates lung inflammation | Q46902221 | ||
| Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening | Q47585614 | ||
| In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury | Q47853089 | ||
| Inhibition of respiratory viruses by nasally administered siRNA. | Q47874231 | ||
| RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts | Q48472950 | ||
| In situ analysis of single-stranded and duplex siRNA integrity in living cells. | Q49075255 | ||
| Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. | Q51562160 | ||
| Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. | Q51582989 | ||
| Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. | Q51829777 | ||
| Chemical modification of siRNAs to improve serum stability without loss of efficacy. | Q53600125 | ||
| RNAi-mediated gene silencing in non-human primates. | Q53630565 | ||
| siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway | Q57374693 | ||
| Fomivirsen for the treatment of cytomegalovirus retinitis | Q77876177 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 443-453 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Interfering with disease: a progress report on siRNA-based therapeutics | |
| P478 | volume | 6 |
| Q35069143 | 2020 Foresight: Envisioning Therapeutic Innovations for Pain |
| Q39922356 | 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma |
| Q58122701 | A Cell-Based High-Throughput Assay for Gap Junction Communication Suitable for Assessing Connexin 43–Ezrin Interaction Disruptors Using IncuCyte ZOOM |
| Q33330928 | A combinatorial library of lipid-like materials for delivery of RNAi therapeutics |
| Q38095502 | A daunting task: manipulating leukocyte function with RNAi |
| Q36713994 | A microcosm of the biomedical research experience for upper-level undergraduates |
| Q36061347 | A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo. |
| Q33712960 | A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells |
| Q39010137 | A new spiral microelectrode assembly for electroporation and impedance measurements of adherent cell monolayers. |
| Q40090404 | A novel dual lock method for down-regulation of genes, in which a target mRNA is captured at 2 independent positions by linked locked nucleic acid antisense oligonucleotides |
| Q30847307 | A retro-inverso cell-penetrating peptide for siRNA delivery. |
| Q34514698 | A simplified and versatile system for the simultaneous expression of multiple siRNAs in mammalian cells using Gibson DNA Assembly |
| Q39549419 | A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer |
| Q34013891 | A status report on RNAi therapeutics |
| Q35155064 | Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics |
| Q39391675 | Adenovirus-mediated RNA interference targeting FOXM1 transcription factor suppresses cell proliferation and tumor growth of nasopharyngeal carcinoma |
| Q90076035 | Advanced in developmental organic and inorganic nanomaterial: a review |
| Q41786279 | Advances in Lipid Nanoparticles for siRNA Delivery |
| Q37221070 | Advances with microRNAs in Parkinson's disease research |
| Q28392004 | Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems |
| Q42781100 | Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy |
| Q24562178 | Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy |
| Q87765416 | Amelioration of colorectal cancer using negative lipidoid nanoparticles to encapsulate siRNA against APRIL by enema delivery mode |
| Q93182196 | Amphiphilic Peptides for Efficient siRNA Delivery |
| Q34901473 | An RGD-modified MRI-visible polymeric vector for targeted siRNA delivery to hepatocellular carcinoma in nude mice |
| Q45874701 | An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. |
| Q39642482 | An efficient and high-throughput electroporation microchip applicable for siRNA delivery. |
| Q36691077 | An integrated miRNA functional screening and target validation method for organ morphogenesis |
| Q42732964 | An ion switch regulates fusion of charged membranes |
| Q35907382 | Analysis of Host Gene Expression Profile in HIV-1 and HIV-2 Infected T-Cells |
| Q39773875 | Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo. |
| Q48062921 | Anionic Polymer and Quantum Dot Excipients to Facilitate siRNA Release and Self-Reporting of Disassembly in Stimuli-Responsive Nanocarrier Formulations. |
| Q26828464 | Anti-HIV-1 nanotherapeutics: promises and challenges for the future |
| Q36962681 | Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells |
| Q37189998 | Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? |
| Q34021708 | Application of OMICS technologies in occupational and environmental health research; current status and projections |
| Q39474528 | Application of allele-specific RNAi in hepatitis B virus lamivudine resistance |
| Q31084885 | Application of high-resolution ESI and MALDI mass spectrometry to metabolite profiling of small interfering RNA duplex |
| Q33717239 | Aptamer-targeted cell-specific RNA interference |
| Q47131796 | As Technologies for Nucleotide Therapeutics Mature, Products Emerge |
| Q38848955 | Assembling Mn:ZnSe quantum dots-siRNA nanoplexes for gene silencing in tumor cells |
| Q37841818 | Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells |
| Q34457509 | Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. |
| Q53436494 | Asymmetric RNA duplexes mediate RNA interference in mammalian cells. |
| Q40116203 | Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass |
| Q35080089 | Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors |
| Q33923403 | Attenuation of fibrosis in vitro and in vivo with SPARC siRNA |
| Q41380434 | Autonomously folded α-helical lockers promote RNAi |
| Q35857347 | Biocompatible and colloidally stabilized mPEG-PE/calcium phosphate hybrid nanoparticles loaded with siRNAs targeting tumors |
| Q37378340 | Biological barriers to therapy with antisense and siRNA oligonucleotides |
| Q39859749 | Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf |
| Q26773973 | Bone site-specific delivery of siRNA |
| Q64261924 | Bottlebrush-architectured poly(ethylene glycol) as an efficient vector for RNA interference in vivo |
| Q50428326 | Branch-PCR Constructed Stable shRNA Transcription Nanoparticles Have Long-Lasting RNAi Effect. |
| Q34725471 | Branched RNA: A New Architecture for RNA Interference |
| Q42425233 | CCL26-targeted siRNA treatment of alveolar type II cells decreases expression of CCR3-binding chemokines and reduces eosinophil migration: implications in asthma therapy |
| Q37424823 | CELL-SELEX: Novel perspectives of aptamer-based therapeutics |
| Q43241712 | Calculation of hydrodynamic properties for G-quadruplex nucleic acid structures from in silico bead models |
| Q35823611 | Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group |
| Q48687614 | Cationic fluorescent polymer core-shell nanoparticles for encapsulation, delivery, and non-invasively tracking the intracellular release of siRNA. |
| Q41471538 | Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics |
| Q41732280 | Cell type-specific delivery of short interfering RNAs by dye-functionalised theranostic nanoparticles |
| Q38974236 | Cell-Penetrating Peptides-Mechanisms of Cellular Uptake and Generation of Delivery Systems. |
| Q33834772 | Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy |
| Q39934164 | Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier |
| Q81985022 | Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides |
| Q37976494 | Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics |
| Q38162098 | Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology |
| Q84878083 | Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery |
| Q64376603 | Characterization of the essential role of bone morphogenetic protein 9 (BMP9) in osteogenic differentiation of mesenchymal stem cells (MSCs) through RNA interference |
| Q37655882 | Chemical modification of siRNA. |
| Q48282746 | Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy. |
| Q48569299 | Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs |
| Q42486590 | Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins |
| Q42045871 | Chitosan combined with poly-L-arginine as efficient, safe, and serum-insensitive vehicle with RNase protection ability for siRNA delivery |
| Q38122934 | Chitosans for delivery of nucleic acids. |
| Q38633261 | Clinical experiences with systemically administered siRNA-based therapeutics in cancer |
| Q37138654 | Clinical significance of TIPE expression in gastric carcinoma |
| Q33869361 | Clinical status of duplex RNA |
| Q38383297 | Clinical translation of RNAi-based treatments for respiratory diseases |
| Q36838738 | Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region |
| Q38889403 | Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles |
| Q39042837 | Co-delivery of small interfering RNA using a camptothecin prodrug as the carrier |
| Q50534472 | Co-transfection and tandem transfection of HEK293A cells for overexpression and RNAi experiments. |
| Q36294386 | Combining phylogenetic footprinting with motif models incorporating intra-motif dependencies. |
| Q36959594 | Comparison between the repression potency of siRNA targeting the coding region and the 3'-untranslated region of mRNA. |
| Q37157241 | Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells |
| Q38313803 | Computational design of artificial RNA molecules for gene regulation |
| Q37111373 | Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice |
| Q55280847 | Construction of histidine-containing hydrocarbon stapled cell penetrating peptides for in vitro and in vivo delivery of siRNAs. |
| Q38102611 | Current progress for the use of miRNAs in glioblastoma treatment |
| Q37940340 | Current progress in the development of RNAi-based therapeutics for HIV-1 |
| Q30574647 | Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics |
| Q39866360 | DNA end-processing enzyme polynucleotide kinase as a potential target in the treatment of cancer |
| Q37636194 | Degradable Dextran Nanopolymer as a Carrier for Choline Kinase (ChoK) siRNA Cancer Therapy |
| Q35046391 | Degradable polyelectrolyte multilayers that promote the release of siRNA |
| Q38226666 | Delivering the promise of small ncRNA therapeutics |
| Q91992110 | Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133 |
| Q37155836 | Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction |
| Q38160246 | Delivery of RNAi therapeutics: work in progress |
| Q48418503 | Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer |
| Q35982462 | Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer |
| Q28087352 | Delivery of nucleic acids and nanomaterials by cell-penetrating peptides: opportunities and challenges |
| Q35903717 | Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers |
| Q38853191 | Delivery strategies and potential targets for siRNA in major cancer types |
| Q34946937 | Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo |
| Q34644554 | Designing highly active siRNAs for therapeutic applications. |
| Q36645940 | Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis |
| Q35816825 | Development and optimization of nanosomal formulations for siRNA delivery to the liver |
| Q92735257 | Development of elastin-like polypeptide for targeted specific gene delivery in vivo |
| Q39506235 | Development of lipidoid-siRNA formulations for systemic delivery to the liver |
| Q46205464 | Development of quantitative molecular clinical end points for siRNA clinical trials |
| Q35380932 | Development of small RNA delivery systems for lung cancer therapy. |
| Q34288026 | Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation |
| Q28477376 | Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles |
| Q30501927 | Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. |
| Q37277677 | Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer |
| Q41197665 | Diseases originate and terminate by genes: unraveling nonviral gene delivery |
| Q58073588 | Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA |
| Q39616606 | Disulfide-based poly(amido amine)s for siRNA delivery: effects of structure on siRNA complexation, cellular uptake, gene silencing and toxicity |
| Q50973677 | Down-regulation of Smad3 accelerates palatal wound repair. |
| Q35024012 | Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition |
| Q36984469 | Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras |
| Q34080079 | Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters |
| Q42389499 | Effect of nanoparticle conjugation on gene silencing by RNA interference |
| Q39005051 | Effective inhibition of Japanese encephalitis virus replication by shRNAs targeting various viral genes in vitro and in vivo |
| Q36844506 | Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes |
| Q35855686 | Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells. |
| Q36893517 | Effects of local mRNA structure on posttranscriptional gene silencing |
| Q39726190 | Efficient and gentle siRNA delivery by magnetofection |
| Q34149828 | Efficient and targeted delivery of siRNA in vivo |
| Q37053575 | Efficient downregulation of VEGF in retinal pigment epithelial cells by integrin ligand-labeled liposome-mediated siRNA delivery |
| Q46584676 | Efficient in vivo microRNA targeting of liver metastasis |
| Q92341122 | Efficient nanocarriers of siRNA therapeutics for cancer treatment |
| Q39850218 | Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein |
| Q37328068 | Efficient siRNA delivery with non-viral polymeric vehicles |
| Q41845496 | Efficient siRNA transfection to the inner ear through the intact round window by a novel proteidic delivery technology in the chinchilla |
| Q37588723 | Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease |
| Q47105498 | Engineered Zn(II)-Dipicolylamine-Gold Nanorod Provides Effective Prostate Cancer Treatment by Combining siRNA Delivery and Photothermal Therapy |
| Q37849727 | Engineering Nanocarriers for siRNA Delivery. |
| Q37709610 | Engineering RNA for targeted siRNA delivery and medical application |
| Q34516023 | Enrichment of intersubtype HIV-1 recombinants in a dual infection system using HIV-1 strain-specific siRNAs |
| Q37119723 | Epithelial cell apoptosis and neutrophil recruitment in acute lung injury-a unifying hypothesis? What we have learned from small interfering RNAs |
| Q58693217 | Evaluation of Amino-Functional Polyester Dendrimers Based on Bis-MPA as Nonviral Vectors for siRNA Delivery |
| Q57803478 | Expression profiles and prognostic value of miRNAs in retinoblastoma |
| Q80757144 | FXTAS: a bad RNA and a hope for a cure |
| Q37442480 | Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells |
| Q39521378 | Fluorescence cross-correlation spectroscopy reveals mechanistic insights into the effect of 2'-O-methyl modified siRNAs in living cells |
| Q35909205 | Formulation Strategies, Characterization, and In Vitro Evaluation of Lecithin-Based Nanoparticles for siRNA Delivery |
| Q28115088 | Foxp3 is critical for human natural CD4+CD25+ regulatory T cells to suppress alloimmune response |
| Q33999330 | From gene delivery to gene silencing: plasmid DNA-transfecting cationic lipid 1,3-dimyristoylamidopropane-2-[bis(2-dimethylaminoethane)] carbamate efficiently promotes small interfering RNA-induced RNA interference |
| Q37763427 | Frontiers of mass spectrometry in nucleic acids analysis. |
| Q36512567 | Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge |
| Q38928987 | Functional peptides for siRNA delivery |
| Q86953058 | Gene silencing and antitumoral effects of Eg5 or Ran siRNA oligoaminoamide polyplexes |
| Q34365466 | Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA |
| Q37956945 | Gene-based therapies for dominantly inherited retinopathies |
| Q44791097 | Glutathione-responsive nano-transporter-mediated siRNA delivery: silencing the mRNA expression of Ras. |
| Q47578379 | Grand challenges in modulating the immune response with RNAi nanomedicines. |
| Q40037564 | HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region |
| Q35673875 | Harnessing RNAi nanomedicine for precision therapy |
| Q39027891 | Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. |
| Q38930049 | Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy |
| Q52316104 | Hexadecylated linear PEI self-assembled nanostructures as efficient vectors for neuronal gene delivery. |
| Q38541526 | Highlighting the role of polymer length, carbohydrate size, and nucleic acid type in potency of glycopolycation agents for pDNA and siRNA delivery |
| Q44396769 | Highly potent and stable capped siRNAs with picomolar activity for RNA interference |
| Q36708805 | Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer |
| Q33586461 | Huntington's disease: silencing a brutal killer |
| Q33669734 | Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection |
| Q41290606 | Hybridisation potential of 1',3'-Di-O-methylaltropyranoside nucleic acids |
| Q54207404 | Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus. |
| Q30404683 | Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1. |
| Q36973296 | In Vivo GFP Knockdown by Cationic Nanogel-siRNA Polyplexes |
| Q35140847 | In vitro evaluation of optimized liposomes for delivery of small interfering RNA. |
| Q42426586 | In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). |
| Q37718105 | In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. |
| Q39882078 | Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide |
| Q37489356 | Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles |
| Q47351371 | Influence of the size and charge of gold nanoclusters on complexation with siRNA: a molecular dynamics simulation study. |
| Q45884239 | Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer |
| Q55056421 | Inhibition of thimet oligopeptidase by siRNA alters specific intracellular peptides and potentiates isoproterenol signal transduction. |
| Q35000572 | Intelligent Nanoparticles for Advanced Drug Delivery in Cancer Treatment |
| Q57363419 | Intelligent nucleic acid delivery systems based on stimuli-responsive polymers |
| Q37275462 | Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis |
| Q64102250 | Intratracheal Administration of siRNA Triggers mRNA Silencing in the Lung to Modulate T Cell Immune Response and Lung Inflammation |
| Q28384959 | Ischemia-induced autophagy contributes to neurodegeneration in cerebellar Purkinje cells in the developing rat brain and in primary cortical neurons in vitro |
| Q38232125 | LC-MS of oligonucleotides: applications in biomedical research |
| Q42238107 | Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing |
| Q42215793 | Lentiviral-mediated RNAi targeting caspase-3 inhibits apoptosis induced by serum deprivation in rat endplate chondrocytes in vitro |
| Q34199790 | Light-Induced Content Release from Plasmon Resonant Liposomes |
| Q35598648 | Light-mediated activation of siRNA Release in diblock copolymer assemblies for controlled gene silencing |
| Q39146587 | Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer |
| Q39339170 | Lipid nanoparticles for hepatic delivery of small interfering RNA. |
| Q38269558 | Lipid nanoparticles for short interfering RNA delivery |
| Q36588308 | Lipid-like Nanoparticles for Small Interfering RNA Delivery to Endothelial Cells |
| Q30422001 | Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity |
| Q83080136 | Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice |
| Q35846845 | Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery. |
| Q27022363 | MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications |
| Q37213586 | Maintaining the silence: reflections on long-term RNAi |
| Q37695149 | Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. |
| Q45879871 | Matrix metalloproteinase-inspired suicidal treatments of diabetic ulcers with siRNA-decorated nanofibrous meshes |
| Q36315291 | Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo |
| Q37193000 | Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides |
| Q33393397 | Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses |
| Q36725131 | MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). |
| Q39895165 | MicroRNA-like off-target transcript regulation by siRNAs is species specific. |
| Q26824024 | MicroRNAs as pharmacological targets in diabetes |
| Q37946984 | MicroRNAs in neurodegenerative diseases and their therapeutic potential. |
| Q37499332 | Micromanagers of immune cell fate and function |
| Q36963243 | Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants |
| Q34276290 | Multifunctional gold nanorods for siRNA gene silencing and photothermal therapy |
| Q37137333 | N-Alkyl-PEI-functionalized iron oxide nanoclusters for efficient siRNA delivery |
| Q45883154 | NIR light controlled photorelease of siRNA and its targeted intracellular delivery based on upconversion nanoparticles. |
| Q42339315 | Nano-based delivery of RNAi in cancer therapy |
| Q34622662 | Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances |
| Q37601740 | Nanomaterials for cancer therapy and imaging |
| Q38794563 | Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells |
| Q38874499 | Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy |
| Q37397058 | Nanoparticles and their applications in cell and molecular biology |
| Q38120408 | Nanostructure-induced DNA condensation |
| Q33420721 | Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons |
| Q35293673 | Nasal mucosal microRNA expression in children with respiratory syncytial virus infection |
| Q35190149 | Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery |
| Q33710058 | Non-viral siRNA delivery into the mouse retina in vivo |
| Q39101363 | Nonendocytic delivery of lipoplex nanoparticles into living cells using nanochannel electroporation |
| Q40332893 | Nonhuman primates as models for the discovery and development of ebolavirus therapeutics |
| Q37024768 | Nonviral delivery of synthetic siRNAs in vivo |
| Q39999697 | Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2. |
| Q37360226 | Nonviral methods for siRNA delivery |
| Q88954180 | Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation |
| Q35576275 | Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells |
| Q37678180 | Novel RNA-based strategies for therapeutic gene silencing |
| Q36673371 | Novel functions for small RNA molecules |
| Q36512557 | Novel protein transduction domain mimics as nonviral delivery vectors for siRNA targeting NOTCH1 in primary human T cells. |
| Q27657724 | Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes |
| Q34011377 | Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection. |
| Q37079391 | Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses |
| Q37803214 | Oligonucleotide delivery in cancer therapy |
| Q42212130 | Oligonucleotide delivery to the lung: waiting to inhale. |
| Q35163373 | Oligonucleotide delivery: a patent review (2010 - 2013). |
| Q22306293 | Oligonucleotide therapeutic approaches for Huntington disease |
| Q39175404 | Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy |
| Q36173624 | On future's doorstep: RNA interference and the pharmacopeia of tomorrow |
| Q37386576 | On the use of short-interfering RNA to study alcohol-related genes |
| Q37777745 | Oncolytic-adenovirus-expressed RNA interference for cancer therapy |
| Q48116928 | Optimized Solid-Phase-Assisted Synthesis of Oleic Acid Containing siRNA Nanocarriers |
| Q36053828 | Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation. |
| Q39344589 | Optimizing siRNA efficacy through alteration in the target cell-adhesion substrate interaction |
| Q39150052 | Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery. |
| Q45965985 | PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. |
| Q40587272 | PEG-PLA nanoparticles facilitate siRNA knockdown in adult zebrafish heart |
| Q37347451 | Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems |
| Q38100809 | Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine |
| Q33776507 | Pharmacologic advances in the treatment and prevention of respiratory syncytial virus |
| Q36331548 | Phosphorothioate oligonucleotide quantification by μ-liquid chromatography-mass spectrometry |
| Q33554206 | Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses |
| Q39491862 | Physicochemical and biological evaluation of siRNA polyplexes based on PEGylated Poly(amido amine)s. |
| Q28384723 | Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis |
| Q37613212 | Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo |
| Q35778918 | Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. |
| Q47130088 | Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease |
| Q41985187 | Polyethylenimine-mediated gene delivery to the lung and therapeutic applications. |
| Q35161952 | Porous silicon microparticles for delivery of siRNA therapeutics |
| Q88584498 | Porous silicon-graphene oxide core-shell nanoparticles for targeted delivery of siRNA to the injured brain |
| Q35261143 | Possibilities for RNA interference in developing hepatitis C virus therapeutics |
| Q39911415 | Post-transcriptional silencing of CCR3 downregulates IL-4 stimulated release of eotaxin-3 (CCL26) and other CCR3 ligands in alveolar type II cells |
| Q38843670 | Powering up the molecular therapy of RNA interference by novel nanoparticles |
| Q38778452 | Precise and efficient siRNA design: a key point in competent gene silencing |
| Q52840762 | Precise redox-sensitive cleavage sites for improved bioactivity of siRNA lipopolyplexes. |
| Q28085290 | Preclinical and clinical development of siRNA-based therapeutics |
| Q36907352 | Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells |
| Q40018285 | Profiling essential genes in human mammary cells by multiplex RNAi screening |
| Q37477571 | Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. |
| Q37478933 | Progress in microRNA delivery |
| Q37419313 | Progress in the therapeutic applications of siRNAs against HIV-1. |
| Q38160537 | Progress towards the prevention and treatment of norovirus infections |
| Q33902729 | Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles. |
| Q33687357 | Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles |
| Q54790224 | RIG-ing an antitumor response. |
| Q37292432 | RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges |
| Q34729434 | RNA interference for improving the outcome of islet transplantation. |
| Q39208846 | RNA interference targeting human FAK and EGFR suppresses human non-small-cell lung cancer xenograft growth in nude mice |
| Q45372948 | RNA interference therapy in lung transplant patients infected with respiratory syncytial virus |
| Q38019046 | RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics |
| Q37333053 | RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy |
| Q37102336 | RNA interference: an emerging generation of biologicals |
| Q34248493 | RNA therapeutics: beyond RNA interference and antisense oligonucleotides |
| Q90481781 | RNA-based scaffolds for bone regeneration: application and mechanisms of mRNA, miRNA and siRNA |
| Q58061971 | RNAi in Respiratory Diseases |
| Q38541950 | RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies |
| Q34303837 | RNAi-based therapies for Huntington's disease: delivery challenges and opportunities |
| Q33426864 | RNAi-mediated c-Rel silencing leads to apoptosis of B cell tumor cells and suppresses antigenic immune response in vivo |
| Q33652451 | RNAi-microsponges form through self-assembly of the organic and inorganic products of transcription |
| Q37871417 | RNAi: a potential new class of therapeutic for human genetic disease |
| Q36914607 | Rational design of novel N-alkyl-N capped biostable RNA nanostructures for efficient long-term inhibition of gene expression |
| Q46247007 | Reactive oxygen species (ROS)-responsive nanomedicine for RNAi-based cancer therapy. |
| Q34165321 | Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors |
| Q38241667 | Recent advances in characterization of nonviral vectors for delivery of nucleic acids: impact on their biological performance |
| Q37665303 | Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application |
| Q39225594 | Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA. |
| Q37019488 | Redox-based control of the transformation and activation of siRNA complexes in extracellular environments using ferrocenyl lipids |
| Q33840252 | Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease |
| Q34609025 | Regulation of mRNA translation in renal physiology and disease |
| Q37896464 | Research progress on siRNA delivery with nonviral carriers |
| Q37626377 | Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities |
| Q37012057 | Roles of microRNAs and their targets in cancer |
| Q33302103 | SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas |
| Q61796229 | Selective Capture and Purification of MicroRNAs and Intracellular Proteins through Antisense-vectorized Magnetic Nanobeads |
| Q21245112 | Selective gene silencing by viral delivery of short hairpin RNA |
| Q47212600 | Self-Transfecting Micellar RNA: Modulating Nanoparticle Cell Interactions via High Density Display of Small Molecule Ligands on Micelle Coronas |
| Q39515368 | Self-assembled multifunctional nanoplexes for gene inhibitory therapy |
| Q34005639 | Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy |
| Q39362625 | Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines. |
| Q34764750 | Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 |
| Q64119071 | Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication |
| Q36666473 | Signalosomes as Therapeutic Targets |
| Q34297263 | Significance and applications of nanoparticles in siRNA delivery for cancer therapy |
| Q41009240 | Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice |
| Q33570738 | Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo |
| Q36341509 | Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224. |
| Q37553822 | Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV |
| Q35930516 | Single base mismatches in the mRNA target site allow specific seed region-mediated off-target binding of siRNA targeting human coagulation factor 7. |
| Q38705406 | Single-chain antibody-delivered Livin siRNA inhibits human malignant melanoma growth in vitro and in vivo |
| Q37703070 | Site-specific gene therapy for cardiovascular disease. |
| Q34655823 | Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer |
| Q34890347 | Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures |
| Q34552948 | Small interfering RNA-based molecular therapy of cancers |
| Q37182706 | Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth |
| Q40026760 | Small interfering RNA-mediated silencing of glutathione-S-transferase A1 sensitizes hepatic carcinoma cells to photodynamic therapy with pentaphyrins |
| Q38014586 | Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. |
| Q42912325 | Solid-Supported Synthesis and Click Conjugation of 4′-C-Alkyne Functionalized Oligodeoxyribonucleotides |
| Q37864924 | Special delivery: targeted therapy with small RNAs. |
| Q38606476 | Src Family Kinases in Brain Edema After Acute Brain Injury |
| Q39317131 | Stability study of unmodified siRNA and relevance to clinical use. |
| Q35661857 | Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers. |
| Q37640468 | Stable RNA nanoparticles as potential new generation drugs for cancer therapy |
| Q36755506 | Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate |
| Q38017713 | Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers |
| Q37619111 | Strategies for targeted nonviral delivery of siRNAs in vivo |
| Q27653175 | Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex |
| Q27651827 | Structure of the guide-strand-containing argonaute silencing complex |
| Q36091258 | Structure-Based Design of Dendritic Peptide Bolaamphiphiles for siRNA Delivery |
| Q37688113 | Study on the Biological Characteristics of CD133 (+) Cells Interfered by RNA Interference in Gastric Cancer |
| Q37950261 | Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. |
| Q37665298 | Subcellular targeting strategies for drug design and delivery |
| Q35227744 | Surface modification of silica particles with gold nanoparticles as an augmentation of gold nanoparticle mediated laser perforation |
| Q39831016 | Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery |
| Q40119079 | Synergic silencing of costimulatory molecules prevents cardiac allograft rejection |
| Q39631363 | Synthesis and properties of small interfering RNA duplexes carrying 5-ethyluridine residues. |
| Q49073854 | Synthesis of Poly Linear shRNA Expression Cassettes Through Branch-PCR. |
| Q33825496 | Synthesis of lipid-oligonucleotide conjugates for RNA interference studies. |
| Q43858618 | Systematic optimization of ion-pairing agents and hexafluoroisopropanol for enhanced electrospray ionization mass spectrometry of oligonucleotides |
| Q35623481 | Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice |
| Q37469987 | Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. |
| Q27311589 | Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets |
| Q35802115 | Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. |
| Q90709590 | Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles |
| Q45871847 | TGF-β₁-siRNA delivery with nanoparticles inhibits peritoneal fibrosis |
| Q37141990 | Target validation to biomarker development: focus on RNA interference |
| Q41768037 | Targeted delivery of siRNA to cell death proteins in sepsis. |
| Q34389283 | Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation |
| Q39539998 | Targeted delivery to neuroblastoma of novel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterol-based post-insertion method |
| Q37356199 | Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug |
| Q37068706 | Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? |
| Q38840921 | Targeting MicroRNAs Involved in the BDNF Signaling Impairment in Neurodegenerative Diseases. |
| Q37298570 | Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth |
| Q37778399 | Targeting miRNAs in osteoblast differentiation and bone formation |
| Q42322516 | Targeting of phage particles towards endothelial cells by antibodies selected through a multi-parameter selection strategy. |
| Q36533706 | Targeting of tetraspanin proteins--potential benefits and strategies |
| Q26781574 | Targeting protein-protein interactions in complexes organized by A kinase anchoring proteins |
| Q28087657 | Technologies for controlled, local delivery of siRNA |
| Q39227810 | The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market |
| Q38382964 | The application of RNAi-based treatments for inflammatory bowel disease |
| Q37780444 | The application of ribozymes and DNAzymes in muscle and brain. |
| Q28245865 | The miR-34 family in cancer and apoptosis |
| Q37140008 | The potential of RNA interference-based therapies for viral infections |
| Q38198726 | The role of transcription factors in prostate cancer and potential for future RNA interference therapy |
| Q38819540 | The spacer arm length in cell-penetrating peptides influences chitosan/siRNA nanoparticle delivery for pulmonary inflammation treatment |
| Q38978890 | The use of pH-sensitive functional selenium nanoparticles shows enhanced in vivo VEGF-siRNA silencing and fluorescence imaging |
| Q36897394 | The versatility of oligonucleotides as potential therapeutics |
| Q36411370 | Therapeutic accessibility of caspase-mediated cell death as a key pathomechanism in indirect acute lung injury |
| Q24669624 | Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? |
| Q37038988 | Therapeutic applications of aptamers |
| Q33921112 | Therapeutic effects of long-circulating miR-135a-containing cationic immunoliposomes against gallbladder carcinoma |
| Q24655262 | Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model |
| Q37414354 | Therapeutic potential of RNA interference in drug-resistant cancers |
| Q37169944 | Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. |
| Q81227736 | Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells |
| Q47570622 | Toxicity profiling of several common RNAi-based nanomedicines: a comparative study |
| Q33848915 | TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery |
| Q45214606 | Translating materials design to the clinic |
| Q36076260 | Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery |
| Q58700887 | Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles |
| Q37230918 | Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics |
| Q30581724 | Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer |
| Q33630968 | Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment |
| Q36184758 | Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology |
| Q36263009 | Unrealistic phylogenetic trees may improve phylogenetic footprinting |
| Q33953110 | Vectors and parameters that enhance the efficacy of RNAi-mediated gene disruption in transgenic Drosophila |
| Q33716038 | Versatile RNA interference nanoplatform for systemic delivery of RNAs. |
| Q41928019 | Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer siRNA Therapy In Vivo. |
| Q34700581 | Visualizing the attack of RNase enzymes on dendriplexes and naked RNA using atomic force microscopy |
| Q49808510 | [Construction and verification of anti-MM scFv-tP fusion protein expression vector]. |
| Q24649056 | miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells |
| Q38521725 | microRNA therapies in cancer |
| Q50056659 | microRNA-219 Reduces Viral Load and Pathologic Changes in Theiler's Virus-Induced Demyelinating Disease. |
| Q57374236 | pH-sensitive siRNA delivery systems |
| Q33705663 | siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection |
| Q37166074 | siRNA and the lung: research tool or therapeutic drug? |
| Q51713721 | siRNA delivery into cultured primary human myoblasts--optimization of electroporation parameters and theoretical analysis. |
| Q38043064 | siRNA delivery: from lipids to cell-penetrating peptides and their mimics |
| Q38074462 | siRNA therapeutics in the treatment of diseases. |
| Q37718205 | siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer |
| Q33925270 | siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract |
| Q41881864 | siRNA-optimized Modifications for Enhanced In Vivo Activity |
| Q38229425 | siRNA: novel therapeutics from functional genomics |
| Q42905735 | siRNAs targeted to Smad4 prevent renal fibrosis in vivo |
| Q43122577 | siRecords: a database of mammalian RNAi experiments and efficacies |
Search more.